Claims
- 1. Human neural or neuronal progenitor cells isolated from non-embryonal human brain tissue.
- 2. The human neural or neuronal progenitor cells according to claim 1, wherein the progenitor cells are isolated from the brain's ependyma and subependyma.
- 3. The human neural or neuronal progenitor cells according to claim 1, wherein the cells express an RNA-binding protein which characterizes an early neural or neuronal phenotype.
- 4. The human neural progenitor cells according to claim 3, wherein the RNA-binding protein is a mushashi protein.
- 5. The human neuronal progenitor cells according to claim 3, wherein the RNA-binding protein is a Hu protein.
- 6. The human neural or neuronal progenitor cells according to claim 5, wherein the Hu protein is selected from the group consisting of HuD, HuC, and HelN1.
- 7. A method of propagating neurons from progenitor cells derived from human brain tissue comprising:
applying serially FGF2 and BDNF to the progenitor cells.
- 8. The method according to claim 8 further comprising:
applying IGFI to the progenitor cells.
- 9. The method according to claim 7, wherein the cells are propagated in culture
- 10. The method according to claim 7, wherein the brain tissue is fetal brain tissue.
- 11. The method according to claim 7, wherein the brain tissue is juvenile or adult brain tissue.
- 12. The method according to claim 7, wherein the cells are propagated in situ.
- 13. The method according to claim 12, wherein the brain tissue contains subependymal, subcortical, or cortical progenitors.
- 14. A method of treating neurological damage by transplanting or implanting neuronal progenitor cells into a human brain comprising:
providing isolated adult human neuronal progenitor cells; and transplanting or implanting said progenitor cells to the brain of a human patient.
- 15. The method according to claim 14, wherein the neural or neuronal progenitor cells are transplanted or implanted into the brain's subendyma of the human neonatal or post-natal ventricular wall.
- 16. The method according to claim 14, wherein the neurological damage resulted from a degenerative neurological disease.
- 17. The method according to claim 16, wherein the patient suffers from Parkinson's disease.
- 18. The method according to claim 16, wherein the patient suffers from a demyelinating disease.
- 19. The method according to claim 14, wherein the neurological damage resulted from ischemic conditions or stroke.
- 20. The method according to claim 14, wherein the neurological damage resulted from traumatic brain injury.
- 21. A method of enhancing survival and function of neural or neuronal precursor cells and cells descending from the neural or neuronal precursor cells comprising:
transducing neural or neuronal precursor cells with a gene encoding an autocrine neurotrophin or an adhesion molecule.
- 22. The method according to claim 21, wherein the gene encodes an autocrine neurotrophin which is selected from the group consisting of FGF2, BDNF, and IGF1.
- 23. A neuronal precursor cell produced by the method of claim 21.
- 24. The neuronal precursor cell according to claim 24, wherein the autocrine neurotrophin is selected from the group consisting of FGF2, BDNF, and IGF1.
- 25. The method according to claim 21, wherein the gene encodes an adhesion molecule.
- 26. The method according to claim 25, wherein the adhesion molecule is selected from the group consisting of N-CAM, NgCAM, and a member of the integrin-family of proteins.
- 27. A neuronal precursor cell provided by the method of claim 25.
- 28. The neuronal precursor cell according to claim 27, wherein the adhesion molecule is selected from the group consisting of N-CAM, NgCAM, and a member of the integrin-family of proteins.
- 29. A method of detecting neural or neuronal progenitor cells comprising:
providing an antibody directed against a protein which is preferentially associated with neural or neuronal progenitor cells when compared to other cell types; contacting cells with the antibody; and detecting cells which bind to the antibody.
- 30. The method according to claim 29, wherein the protein is a Hu protein.
- 31. The method according to claim 30, wherein the Hu protein is selected from the group consisting of HuD, HuC, and HelN1
- 32. The method according to claim 29, wherein the protein is a musashi protein.
- 33. A method of expressing a gene in the brain of a patient, comprising:
providing isolated postnatal or adult human neuronal progenitor cells; transfecting said cells with the gene; introducing said transfected cells to the brain of a patient; and expressing the gene in the brain of the patient.
- 34. The method according to claim 33, wherein the patient suffers from Tay-Sachs disease.
- 35. The method according to claim 33, wherein the gene encodes hexoseaminidase.
- 36. The method according to claim 33, wherein the patient suffers from a hereditary metabolic disease.
- 37. The method according to claim 36, wherein the hereditary metabolic disease is mucopolysaccharidosis.
- 38. A method of separating human, non-embryonal neural or neuronal progenitor cells from a mixed population of cells from human brain tissue, said method comprising:
selecting a promoter which functions only in said human postnatal neural and neuronal progenitor cells; introducing a nucleic acid molecule encoding a fluorescent protein under control of said promoter into the mixed population of cells; allowing the non-embryonal neural or neuronal progenitor cells thereof to express the fluorescent protein; and separating the fluorescent cells from the mixed population of cells, wherein said separated cells are said neural or neuronal progenitor cells.
- 39. A method according to claim 38, wherein said introducing is selected from the group consisting of viral mediated transformation of the mixed population of cells, electroporation, and liposomal mediated transformation of the mixed population of cells.
- 40. A method according to claim 38, wherein said separating comprises fluorescence activated cell sorting.
- 41. A method according to claim 38, wherein the promoter is selected from a Hu promoter, a Musashi promoter, and a Nestin enhancer-promoter.
Parent Case Info
[0001] The present application claims the benefit of U.S. Provisional Patent Application Serial No. 60/079,226 filed Mar. 25, 1998.
Government Interests
[0002] The subject matter of this application was made with support from the United States Government under Grant Nos. NINDS RO1NS33106 and NINDS RO1NS29813 from the National Institutes of Health. The United States Government may retain certain rights.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60079226 |
Mar 1998 |
US |